A comprehensive prognostic and immune analysis of SFXN1 in Pan-cancer
Research Square
2023
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Background Sideroflexin1 (SFXN1), one of the primary sideroflexin (SFXN) proteins, can transport serine to mitochondria and take part in one-carbon metabolism there, with impact on cell proliferation, differentiation and other activities. Numerous evidence suggested that SFXN1 was intimately associated with lung cancer, glioma, and other cancers, its specific function in other malignancies is unknown. Methods Based on TCGA, HPA, GEPIA, and UALCAN databases, SFXN1 expression, prognostic value, and its correlation with immune cell infiltration were explored. The biological function of SFXN1 was conducted in LUAD cells. Results SFXN1 is highly expressed in a variety of tumors and related to clinicopathological features and prognosis. SFXN1 correlated with T cells and B cells by immune infiltration analysis. Moreover, SFXN1 positively correlated with immune checkpoint genes in many tumors. Loss-of-function assay showed SFXN1 silencing could inhibit cell proliferation, migration, invasion, and enhance apoptosis in LUAD cells. Conclusion The high expression of SFXN1 is associated with tumor prognosis and can serve as a novel biomarker for tumor diagnosis and prognosis, as well as a potential therapeutic target for immunotherapy against cancers.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know